Literature DB >> 10050707

Abnormal cytogenetic clones in patients with aplastic anaemia: response to immunosuppressive therapy.

C G Geary1, C J Harrison, N J Philpott, J M Hows, E C Gordon-Smith, J C Marsh.   

Abstract

We report the response to immunosuppressive therapy with antithymocyte globulin (ATG) and cyclosporin or oxymetholone in 13 cases of aplastic anaemia (AA) with an abnormal cytogenetic clone detected at or sometime after diagnosis. Blood and bone marrow examination showed no distinctive morphological features of myelodysplasia (MDS) at diagnosis. Haematological response occurred promptly in eight cases; the remainder responded after additional immunosuppression with or without oxymetholone. Three patients had a late relapse of AA, treated successfully by allogeneic bone marrow transplantation in one; the others responded to oxymetholone. Transformation to MDS or acute leukaemia was not observed after a median follow-up of 4.1 years (range 1.2-11.2). In four patients the cytogenetic clone disappeared after treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10050707     DOI: 10.1046/j.1365-2141.1999.01187.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

Review 1.  Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis.

Authors:  Ronit Gurion; Anat Gafter-Gvili; Mical Paul; Liat Vidal; Isaac Ben-Bassat; Moshe Yeshurun; Ofer Shpilberg; Pia Raanani
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

2.  Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

Authors:  Elaine M Sloand; Matthew J Olnes; Aarthie Shenoy; Barbara Weinstein; Carol Boss; Kelsey Loeliger; Colin O Wu; Kenneth More; A John Barrett; Phillip Scheinberg; Neal S Young
Journal:  J Clin Oncol       Date:  2010-11-01       Impact factor: 44.544

Review 3.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

4.  Cytogenetic study is not essential in patients with aplastic anemia.

Authors:  Atreyee Dutta; Rajib De; Tuphan K Dolai; Pradip K Mitra; Ajanta Halder
Journal:  Am J Blood Res       Date:  2017-11-01

5.  Risk factors for cytomegalovirus retinitis following bone marrow transplantation from unrelated donors in patients with severe aplastic anemia or myelodysplasia.

Authors:  K Kuriyama; S Todo; S Ikushima; N Fujii; T Yoshihara; K Tsunamoto; M Naya; M Hojo; S Hibi; A Morimoto; S Imashuku
Journal:  Int J Hematol       Date:  2001-12       Impact factor: 2.490

Review 6.  Views on the pathophysiology of aplastic anaemia.

Authors:  Edward C Gordon-Smith; J C Marsh; F M Gibson
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria.

Authors:  Lova Sun; Daria V Babushok
Journal:  Blood       Date:  2020-07-02       Impact factor: 22.113

8.  Two cases of acute myeloblastic leukemia evolving from aplastic anemia.

Authors:  Akihiko Taguchi; Takayuki Tominaga; Yoshitaka Nakamori; Mutsuko Miyazaki; Kenji Shinohara
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.490

9.  Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A.

Authors:  Toshiki Yamada; Hisashi Tsurumi; Senji Kasahara; Takeshi Hara; Michio Sawada; Hisataka Moriwaki
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-10       Impact factor: 4.553

Review 10.  Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).

Authors:  Peter Valent; Friedrich Wimazal; Ilse Schwarzinger; Wolfgang R Sperr; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.